by Entheon Biomedical | May 12, 2021 | Company News
CEO of Entheon Biomedical, Timothy Ko, discusses how the company plans to utilize the psychedelic compound, DMT, to treat a variety of addictions. Episode Summary In this episode of the Psychedelic Spotlight podcast, we spend some time with Timothy Ko who is the CEO...
by Entheon Biomedical | Apr 12, 2021 | Company News
Entheon Biomedical Corp. announced the launch of a psychedelics genetic test kit last week through its wholly owned subsidiary HaluGen Life Sciences Inc. The launch represents the first revenue stream for the company, said CEO Timothy Ko. The test will serve as a...
by Entheon Biomedical | Apr 7, 2021 | Company News
Entheon Launches Psychedelics Pre-Screening Genetic Test Entheon Biomedical Corp. (OTC: ENTBF) a company dedicated to the application of the psychedelic DMT in the treatment of addiction, announced the launch of a psychedelics genetic test kit, through its...
by Entheon Biomedical | Mar 5, 2021 | Company News
Gyroscope Therapeutics – Jessica Stitt was named chief financial officer of London-based Gyroscope Therapeutics Limited. Most recently, she served as the Vice President of Finance and Operations for MyoKardia, Inc., which was acquired by Bristol Myers Squibb in...
by Entheon Biomedical | Mar 3, 2021 | Company News
Entheon Biomedical Announces Nancy Maher, Special Advisor of Data Science and Regulatory Affairs Senior Pharmaceutical & Technology Executive and Current SVP, Chief Information Officer, North America at Kyowa Kirin International plc., Previously of IBM,...
by Entheon Biomedical | Mar 2, 2021 | Company News
SAN DIEGO, March 2, 2021 /PRNewswire/ — NeuroPerspective has released its March/April 2021 issue, featuring its first-ever, comprehensive review of the rapidly-expanding Psychedelic Therapeutics space, where substances formerly relegated to sacramental and/or...
Recent Comments